Halocyclopropyl substituted phenoxyalkanoic acids and esters thereof, having hypocholesteremic activity are prepared via several alternative synthetic approaches, involving as the key reactions interaction of a substituted phenylalkene with a carbene source to introduce the halocyclopropyl moiety, and reaction of a substituted phenol with chloroform and a lower-alkanone in the presence of base, or with a lower-alkyl .alpha.-bromo-alkanoate, to form the phenoxyalkanoic acid moiety.
Improvements in the production of halocyclopropyl-substituted phenoxyalkanoic acids and esters
申请人:STERWIN AG.
公开号:EP0142979A2
公开(公告)日:1985-05-29
A process is provided for production of an alkyl 2-[para-(2-2-dihalocyclopropyl)phenoxy]-2-lower alkyl propionate which comprises treating an alkyl 2-[4-(1-hydroxyethyl)-phenoxy)-2-lower alkyl propanoate (IV) with a phosphorus halide and then with an organic base to produce the corresponding substituted styrene and then treating said styrene with a haloform, a strong alkali and a phase transfer catalyst. This process has given overall yields ten-fold greater than those described in the literature.
[EN] SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS<br/>[FR] COMPOSÉS DE PYRIDOPYRIMIDINONYL SUBSTITUÉS UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2021041588A1
公开(公告)日:2021-03-04
Disclosed are compounds of Formula (I):(I) or a salt thereof, wherein: R1, R2, R4, R5, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK ) and diacylglycerol kinase zeta (DGK ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS
申请人:Bristol-Myers Squibb Company
公开号:US20210061802A1
公开(公告)日:2021-03-04
Disclosed are compounds of Formula (I):
or a salt thereof, wherein: R
1
, R
2
, R
4
, R
5
, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.